ZSCAN18 Inhibitors
Chemicals falling under the category of ZSCAN18 Inhibitors are specialized in targeting different cellular mechanisms, all with the intent of altering or disabling ZSCAN18's activity. They are primarily epigenetic modifiers and protein stabilization disruptors. Agents like 5-Azacytidine and Decitabine modify the epigenetic landscape by affecting DNA methylation, which influences ZSCAN18's ability to bind to its genomic targets. Such epigenetic alterations are known to produce extensive transcriptional changes, affecting the genes that are under ZSCAN18's regulation. On the other hand, Trichostatin A and Vorinostat target histone deacetylases, thereby altering chromatin structure. Chromatin remodeling is pivotal in transcription regulation, and these inhibitors are designed to affect the accessibility of transcription factors like ZSCAN18 to the genomic regions they regulate.
Additionally, several other classes of compounds are used to indirectly inhibit ZSCAN18's function. For instance, CDK inhibitors such as Palbociclib, Alsterpaullone, and Roscovitine focus on blocking cell cycle progression. This is based on the assumption that ZSCAN18 may have cell cycle-regulated targets. Stopping CDKs interferes with this regulation, thus indirectly affecting ZSCAN18's scope. Another notable inhibitor is PU-H71, an HSP90 inhibitor, which could lead to ZSCAN18 degradation. As HSP90 is a chaperone involved in protein stabilization, its inhibition could compromise ZSCAN18's stability and hence its cellular function. Overall, this assortment of chemical inhibitors is aimed at affecting ZSCAN18 through multiple avenues, each tailored to target a distinct cellular process or signaling pathway in which ZSCAN18 is assumed to be involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This cytosine analog works by demethylating DNA and incorporates itself into the DNA strand during replication, thereby altering the ability of ZSCAN18 to recognize and bind to its specific genomic targets. Changes in DNA methylation status can significantly disrupt ZSCAN18's transcriptional activities. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
Similar to 5-Azacytidine, Decitabine is a DNA methyltransferase inhibitor that incorporates into the DNA and inhibits methylation. The absence of methyl groups alters ZSCAN18’s capacity to bind specific DNA sequences, reducing its effectiveness as a transcriptional regulator. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
As a cyclin-dependent kinase (CDK) inhibitor, Alsterpaullone prevents cell cycle progression. This is significant because ZSCAN18's function in gene regulation might be dependent on cell cycle stages. By halting CDKs, Alsterpaullone indirectly affects ZSCAN18's regulatory scope. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor, Palbociclib can disrupt ZSCAN18's role in cell cycle progression. Given ZSCAN18’s role in gene regulation, it's plausible that some of its targets are involved in cell cycle regulation, and inhibition of CDK4/6 will therefore impact ZSCAN18’s functionality. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Yet another CDK inhibitor, Roscovitine, impedes cell cycle progression. This is important as ZSCAN18 is implicated in cell cycle regulation; by halting cell cycle via CDK inhibition, Roscovitine can indirectly hamper ZSCAN18's transcriptional activities. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
This BET bromodomain inhibitor can impede ZSCAN18's interaction with bromodomain-containing proteins that could be crucial for its transcriptional role. By inhibiting this interaction, JQ1 can potentially disturb ZSCAN18's function. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
This MDM2 inhibitor can disturb the p53 pathway. Given ZSCAN18's potential role in gene regulation, it's possible that ZSCAN18 targets include genes in the p53 pathway, thereby Nutlin-3 can indirectly interfere with ZSCAN18's function. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
An inhibitor of the methyltransferase EZH2, GSK126 can influence epigenetic markers that ZSCAN18 recognizes for gene regulation. By inhibiting the addition of these markers, GSK126 can disrupt ZSCAN18's activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
This NF-κB inhibitor can affect ZSCAN18's role in regulating genes that are under NF-κB control, disrupting the transcriptional network in which ZSCAN18 operates. | ||||||